Introduction Generalized pustular psoriasis (GPP) is a rare form of psoriasis (less of 1% of
cases). Currently, GPP is recognized as a clinical entity, distinguished from plaque psoriasis …

Psoriasis pathogenesis is influenced by genetic factors and characterized by a complex
interplay between genetic predisposition and various environmental triggers. These triggers …

Psoriasis is now considered a systemic disease, and several comorbidities have been
described such as cardiovascular diseases, neurologic and psychiatric disorders, chronic …

Psoriasis is now considered to be the cutaneous phenotype of a systemic inflammatory
condition, recognized under the term Psoriatic Disease (PsD). PsD has several …

Introduction The development of several effective biological drugs for moderate-to-severe
plaque psoriasis has dramatically changed the lives of patients. Despite the wide use of …

Objectives We aimed to determine the effectiveness profile of bimekizumab in patients
affected by moderate-to-severe plaque psoriasis with involvement of genitalia. Methods …

Bimekizumab, which suppresses both interleukin (IL)‐17A and IL‐17F, has recently been
approved as a biologic for psoriasis. We aimed to evaluate the real‐world effectiveness and …

Introduction Nowadays, despite the wide availability of biological drugs and apremilast for
psoriasis management, there is always a need for new therapies to customize the …

This review explores the intricate relationship between generalized pustular psoriasis (GPP)
and various systemic diseases, shedding light on the broader impacts of this severe skin …

The management of patients affected by moderate-to-severe psoriasis may be challenging,
in particular in patients with serious infectious diseases [tuberculosis (TB), hepatitis B and C …